Cytokinetics' Heart Drug Aficamten Soars

Cytokinetics heart drug aficamten soars, smashing fifty-two-week high after promising Phase three results for non-obstructive hypertrophic cardiomyopathy, a condition with no approved treatments. The drug showed significant improvements in symptom scores and exercise ability, potentially benefiting over three hundred thousand diagnosed patients in the US. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/d9c9c138534ff5d6